7th European GMP Conference - The biennial No 1 Event in Europe

7th European GMP Conference - The biennial No 1 Event in Europe

Prague, Czech Republic

Course No 15959


Costs

This conference already took place.

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Richard Bonner, Qualified Person and Chairman ECA, UK
Dr Christopher Burgess, Qualified Person and Chairman of ECA‘s Quality Control Working Group, UK
Klaus Eichmüller, Wolnzach, c/o Regional Council Darmstadt, GMP Inspectorate, Germany
Dr Matthias Heuermann, NRW Centre for Health (LZG.NRW), Münster, Germany
Dr Afshin Hosseiny, Qualified Person and Chairman of ECA‘s GDP
Interest Group, UK
Dr Andreas König, Quality König GmbH, Germany
Oliver Küttner, Shire, Austria
JOHANNA LINNOLAHTI, Finnish Medicines Agency FIMEA, Finland
Gert Mølgaard, Chair of ECA‘s Working Group on Validation, Denmark
Tracy Moore, Medicines and Healthcare Products Regulatory Agency, UK
Dr Bernd Renger, Qualified Person and Immediate Past Chair of the EQPA, Germany
Dr Franz Schönfeld, GMP Inspectorate, Germany
Dr Wolfgang Schumacher, Chairman ECA´s IT Compliance Group, Switzerland
Lance Smallshaw, ECA Executive Board Member, Belgium

Objectives

The EU GMP Conference is only offered every two years. This unique conference will discuss current and planned changes to the GMP regulation. All experts and managers involved in GMP compliance activities will have the opportunity to get a comprehensive GMP update and to talk to the leading experts from industry and authority.
Although EU GMP is in the center of attention, a harmonized approach with cGMP from FDA will also be an important aspect of the agenda. For international operating companies both EU GMP and FDA compliance is important and the corporate quality systems need to cover the regulation of both regions.

The agenda will therefore focus on key GMP compliance developments. Attention will be paid on the implementation of these requirements into pharmaceutical quality systems. The ECA Foundation’s objective is to support industry, and therefore current activities as well as guidance documents and SOPs are presented during this conference.

Each Session will have speakers from industry and inspectorates to discuss both expectations and implementation aspects.

We wish you a successful and interesting conference.

Yours sincerely,

Richard M. Bonner
Chairman of the ECA Advisory Board

Target Group

The conference is of particular interest for GMP experts of pharmaceutical companies (e.g. QA, QC, production, distribution, regulatory affairs, validation), of GMP inspectorates and Regulatory Authorities.

Only at this conference - Additional ECA Guidance documents for all participants

ECA Guidance Document on Data Integrity
ECA Guidance Document on OOE and OOT
ECA Good Practice Guide on Validation Version 02
ECA/PQG Guide on Good Distribution Practice

Programme

Session I Current Initiatives in EU and FDA

This session will discuss the latest changes and current initiatives in EU GMP and FDA GMP regulation

Update from recent EU GMP changes

  • Latest Changes in EU Regulations
  • Latest Revisions of the EU GMP Guide and its Annexes
  • New EM Guidelines with impact to GMPs
  • Look over the Pond - Important GMP developments in the US
Mutual Reliance Initiative

Doing business with companies that operate outside of the EU/FDA zones
  • How do I know if the company is producing using equivalent GMPs
  • Do cultural differences matter?
  • How will I know if anything goes wrong?
  • What if I am purchasing through a broker?
  • What is my QP responsible for?
Session II Data Integrity of GMP Data

Data Integrity is one of the top topics since some years. Data Integrity is not very detailed described in the EU GMP Guide. So some national authorities (e.g. MHRA) published interpretations about Data Integrity. Also the FDA has published a Guideline on it. The current status regarding Data Integrity is discussed in this session.

GMP Inspections and Data Integrity – Typical Pitfalls
  • MHRA´s Data Integrity Guideline
  • Authorities expectations
  • Inspection findings
How to train company staff in Data Integrity
  • Training as a QA Tool
  • The special case: Data Integrity Training
  • Case Study
ECA’s Data Integrity Guideline
  • Overview of Data Integrity Interest Group
  • Generation process of this guidance document
  • Structure and content
  • Current status and next steps
Session III Quality Oversight

In FDA Warning Letters the lack of Quality Oversight is often mentioned. How is this been seen from an European perspective? Could the FDA requirement on FDA Quality Metrics could also be used as indicator for quality oversight? These questions will be discussed in this session.

Measuring and Monitoring of Quality Assurance: Regulatory Expectations
  • Legal requirements – EU and international
  • Links to ICH Q8, Q9 and Q 10 - Quality oversight
  • Authority requirements
  • Examples
Quality Oversight – how to make it successful?
  • Building Quality Culture
  • Use of existing Systems
  • Benefits from using KPI Implementation in a pharmaceutical company
  • Regulatory expectations
  • Case Study
Session IV Statistical/reduced Sampling

In the movement of the GMPs in the last years one development could be seen. More focus on statistics. This concerns also sampling. On the other hand industry wants to reduce sampling as sampling is costly. An EU inspector will give an overview about (statistical) GMP sampling requirements and an Industry representative will give practical information regarding reduced sampling.

Sampling – View of an EU GMP Inspector
  • API and finished goods sampling und testing
  • EU GMP Guide sampling requirements
  • Part 1, Chapters 4, 5, 6
  • Part 2, Chapter 7
  • Annexes
  • Other regulations
  • US / FDA Requirements
  • Supplier qualification and audits
  • Reduced testing
  • Statistical sampling
  • Findings
Sampling strategies for raw materials and packaging materials in pharmaceutical
Sampling plans

  • How to define sample size for APIs
  • Excipients
  • Primary Packaging Material
  • Secondary Packaging Material
  • When can sampling be reduced?
  • How to deal with deviations?
Session V Interest Group Meetings – Be involved in the next steps

Get involved in the ECA Working Groups. Each delegate will be invited to discuss the upcoming developments with the Chair/Co-Chairs of the working groups.

Agenda
You can address topics of interest for you and you can provide feedback on the currently planned activities. It is the aim of the Working Group to provide a platform of discussion with both colleagues from industry and regulatory authorities.

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK